Dr. Prashant Kapoor, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 145
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MN license 51957 -
Hematology & Oncology Physician
MN license 51957 -
Internal Medicine Physician
ND license 9565
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Rochester Rochester, MN
- Mayo Clinic Health System - Mankato Mankato, MN
Medical groups
- Mayo Clinic (4,956 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 145
- Services billed
- 10,289
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 78 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 57 | 40 |
| Established patient office or other outpatient visit, 40-54 minutes | 51 | 38 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Rochester, MN | 48 |
| Penicillin V Potassium Other prescribers in Rochester, MN | 27 |
| Revlimid (lenalidomide) | 26 |
| Brukinsa (zanubrutinib) | 24 |
| Lenalidomide | 14 |
| Omeprazole Other prescribers in Rochester, MN | 13 |
| Dexamethasone Other prescribers in Rochester, MN | 12 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Rochester, MN | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $7,465 in total to this clinician.
| Beigene Switzerland GmbH | $3,750 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $3,715 |
| Consulting Fee | $7,169 |
|---|---|
| Travel and Lodging | $275 |
| Food and Beverage | $21.64 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beigene Switzerland GmbH Jan 31, 2025 | Consulting Fee BRUKINSA · Oncology | $3,750 |
| E.r. Squibb & Sons, L.l.c. Feb 5, 2025 | Consulting Fee | $3,419 |
| E.r. Squibb & Sons, L.l.c. Feb 3, 2025 | Travel and Lodging travel to SAN DIEGO, CA | $255 |
| E.r. Squibb & Sons, L.l.c. Feb 3, 2025 | Travel and Lodging travel to SAN DIEGO, CA | $19.63 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $1,357,390 in research payments for these studies, mostly to the institutions running them.
- Phase 2 trial of iberdomide in combination with daratumumab and bortezomib in patients with newly diagnosed multiple myeloma or light chain amyloidosis.
Celgene Corporation - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Active, not recruiting · NCT06223516 - First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04083534 - A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Beigene, Ltd. · Active, not recruiting · NCT05952037 - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
Celgene Corporation - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. - M23-001 - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. - A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with …
E.r. Squibb & Sons, L.l.c. - A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Genzyme Corporation · Recruiting · NCT06630806 - Phase 1/2 Trial of Selinexor in COmbination with Carfilzomib, Pomalidomide and DexamethasonE (SCOPE) for Patients with Proteasome-inhibitor and Immunomodulatory Drug Refractory Multiple Myeloma
Karyopharm Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.